Navigation Links
Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010
Date:10/18/2010

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010 -- DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

Shire plc: Third Quarter 2010 Results Date Notification - October 29, 2010

 

DUBLIN, October 18, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce third quarter 2010 earnings on Friday 29 October, 2010.

Results press release will be 12:00 BST / 07:00 EDT issued at: Investor conference call 14:00 BST / 09:00 EDT time:

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:00 BST/9:00 EDT.

The details of the conference call are as follows: UK dial in: 0844-335-0351 US dial in: 1-866-8048688 or 1-718-3541175 International dial +44-844-335-0351 in: Password/Conf ID: 921 510 Live Webcast: http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website http://www.shire.com/shireplc/en/investors.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact: Investor Relations Souheil Salah (Rest of the World) +44-1256-894-160 Ricki Greenwood (North America) +1-484-595-8517
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Atrium Recognized by New Hampshire Bio/Medical Council
2. Shire Update on ProAmatine(R) (midodrine HCl)
3. Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide
4. Pentasa(R) - Shire Receives Ruling From FDA on Citizens Petition
5. Shire Purchases Strategic Site in Massachusetts
6. Shire Receives LIALDA(R) Paragraph IV Notice Letter From Zydus Pharmaceuticals
7. Area Residents Can Give a Little, Help A Lot at Shires BIG GIVE
8. Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
9. Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
10. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
11. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  A recent study ... only four freestanding hospitals in the country dedicated to ... and reconstructive surgery, concluded that the Surfacide Helios ® ... integral component in reducing bacterial pathogens not killed by ... were published at the American Burn Association,s 49th Annual ...
(Date:3/27/2017)... 27, 2017 LightIntegra Technology Inc. today announced ... Dubiel as President and Chief Executive Officer effective March ... Board of Directors of LightIntegra. Paul Geyer ... LightIntegra. "This is the perfect time ... Executive Officer. We,ve selected a very strong leader at ...
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... ... -centric training, today announced the launch of a new research study, The Business ... skills needed to execute that strategy, and the actual success of achieving individual ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... ... 2017 , ... Golden Triangle Emergency Center will be hosting ... to commemorate the two-year anniversary of the facility. The event will feature refreshments ... years while also familiarizing themselves with the facility. , In the two years ...
(Date:3/25/2017)... ... 2017 , ... Getting earned media coverage meaningful for Garden Media Group's clients ... the year, Garden Media aims to provide material helpful to clients’ goals and bottom ... client’s key messages to gain coveted media placements, Garden Media wows clients year-round. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
Breaking Medicine News(10 mins):